Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes.

British journal of clinical pharmacology - 1 Sept 1990

Dahl-Puustinen M L, Alm C, Bertilsson L, Christenson I, Ostman J, Thunberg E, Wikström I

Abstract excerpt

The pharmacokinetics of a single oral dose of 1.75 mg glibenclamide were studied in 15 healthy Caucasians including five poor metabolisers of debrisoquine and five poor metabolisers of S-mephenytoin. Plasma glibenclamide concentrations and the urinary concentrations of trans-4- and cis-3-hydroxyglibenclamide were analyzed by h.p.l.c. Thirty-six +/- 6% (mean +/- s.d., n = 15) of the given dose of glibenclamide was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Debrisoquin
Share to Hydroxylation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mephenytoin

Share to Metabolic Clearance Rate

Share to Phenotype

Share to Polymorphism, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 2121211
DOI: 10.1111/j.1365-2125.1990.tb03800.x
PMCID: PMC1368152

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes.PMID 2121211Read ↗

Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.Semantic proximity Read ↗

Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine.Semantic proximity Read ↗

Genetically determined adverse drug reactions involving metabolism.Semantic proximity Read ↗

The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine.Semantic proximity Read ↗

Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.Semantic proximity Read ↗

Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.Semantic proximity Read ↗

Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.Semantic proximity Read ↗

Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes.Semantic proximity Read ↗

Clinical consequences of polymorphic drug oxidation.Semantic proximity Read ↗

Pharmacogenetics of Debrisoquine and its Use as a Marker For CYP2D6 Hydroxylation CapacitySemantic proximity Read ↗

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin.Semantic proximity Read ↗

Characterization of stereoselectivity and genetic polymorphism of the debrisoquine hydroxylation in man via analysis of urinary debrisoquine and 4-hydroxydebrisoquine by capillary electrophoresis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.